{
  "ticker": "CVB",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02974355",
  "id": "02974355",
  "pages": 10,
  "price_sensitive": true,
  "date": "20250730",
  "time": "0938",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250730/pdf/06m9hbf7tpyq4h.pdf",
  "summary": "**Appendix 4C & Quarterly Activity Report \u2013 Key Points**  \n\n- **Purchase Orders (POs):**  \n  - 6 POs received in Q4 FY25 (2 HiRise\u2122 devices).  \n  - FY25 total: 26 POs (+18% YoY vs. 22 in FY24).  \n\n- **Financials:**  \n  - **Cash balance:** A$5.0m at quarter end.  \n  - **Receivables + expected collections:** Additional A$5.0m.  \n  - **Cash from operations:** A$0.4m (vs. -A$4.4m in Q3 FY25).  \n  - **Record customer receipts:** A$5.6m in Q4 (+180% QoQ, +180% YoY).  \n\n- **HiRise\u2122 Validation:**  \n  - Progressing with key robotic surgical system vendor; timeline uncertain due to vendor\u2019s internal process.  \n\n- **BMD Module FDA Clearance:**  \n  - 200/400 patient scans completed for comparative analysis with DXA.  \n  - On track for FDA 510(k) clearance in H1 CY26.  \n\n- **Vendor Financing Facility:**  \n  - Finalizing A$18m (\u20ac10m) facility to support leasing options for customers in North America/Europe.  \n\n- **Cash Runway:**  \n  - Q1 FY26 cash flow expected to dip due to seasonal holidays and supplier commitments.  \n  - Anticipated A$1.3m R&D tax incentive receipts in Q1.",
  "usage": {
    "prompt_tokens": 6913,
    "completion_tokens": 329,
    "total_tokens": 7242,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-29T23:49:26.693558"
}